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Abstract
Background: Cardiovascular disease (CVD) risk, although perceived to be high, is often difficult to demonstrate in 
disease free (healthy) obese adults.
Hypothesis: Changes in circadian blood pressure variability (CBPV) and endothelial function (EF) may be early 
correlates of cardiometabolic disorders.
Methods: Asymptomatic men and women in 3 groups: normal weight (n = 10), overweight (n = 10) and obese (n = 15) 
were evaluated. Blood pressure and heart rate were recorded over 7 days: every 30 minutes during the day and every 
60 minutes during the night, by automatic ambulatory monitoring. Resting EF was assessed in a fasting state between 
8-10 AM by brachial ultrasound. Anthropometric and cardiometabolic indicators were measured and correlations with 
CBPV and EF were investigated.
Results: The 3 groups had (Mean(SD)) BMI: 22.6(1.6), 27(3) and 34(5) kg/m2, respectively, weight: 64(16), 79(14), 95(16) 
kg and waist circumference: 79(9), 93(10), 107(13) cm. None in normal-weight or overweight groups had abnormal 
CBPV, while 8 of 15 obese adults had one or more CBPV abnormities (p < 0.05). Obese adults with CBPV abnormalities 
had elevated hs-CRP (15.3(9.3) mg/L), fibrinogen (593(97) mg/dl), fasting serum glucose (102(16) mg/dL), and cardiac 
risk ratios (Total-C/HDL-C: 5.2(1.9), LDL-C/HDL-C: 3.1(1.4)). Adults in the 3 respective groups who did not have CBPV 
abnormalities had flow-mediated brachial artery dilatation (FMD) of 0.22(0.06); 0.20(0.04), 0.23(0.02) mm over resting 
diameter. Obese participants with CBPV abnormalities (Mesor-hypotension, circadian hyper amplitude tension, 
elevated pulse pressure), had attenuated FMD at 78, 52, and 56% of resting reference diameter (means 0.18(0.07), 
0.12(0.08), and 0.13(0.05) mm; p < 0.05), respectively.
Conclusions: Asymptomatic obese adults with abnormal CBPV and EF exhibit unfavorable cardiometabolic profiles.
Introduction
Obesity with its increasing prevalence, and as a conse-
quence of its associated co-morbidities, is rapidly becom-
ing the leading global cause for cardiovascular morbidity
and  mortality  [1,2].  Cardiovascular  disease  (CVD)
remains the number one cause of death, not only in the
United States [3], but also worldwide [4]. The conven-
tional risk factors: age, gender, smoking status, diabetes
mellitus (DM), hypertension (HTN), dyslipidemia (DysL),
and metabolic syndrome (MetS), are all known to have
strong positive associations with the risk for CVD-related
adverse events [5,6]. The obesity epidemic has, however,
altered the paradigm for assessing CVD risk with factors
like DM, HTN, DysL, and the MetS.
Diabetes mellitus, the well-recognized CVD risk equiv-
alent  [7,8],  where  obtaining  tight  glycemic  control  is
thought to reduce the enhanced CVD risk [9], is exacer-
bated  by  the  overweight  or  obese  status.  Due  to  an
increasing recognition that CVD risk remains high when
serum glucose concentrations are greater than 100 mg/dL
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[10], and that this enhanced CVD risk can be covertly
present as far back as 15 years prior to the overt loss of
glycemic control [11], asymptomatic (disease-free) over-
weight or obese adults with prediabetes (ADA criteria: an
impaired fasting glucose (IFG) and/or impaired glucose
tolerance  (IGT)),  could  also  have  an  increased  risk  of
developing CVD [12]. Prediabetes is associated with early
carotid atherosclerosis [13], coronary artery calcification
[14], as well as other vascular abnormalities. Our own
recent  findings  indicate  that  prediabetes  is  associated
with  abnormal  circadian  BP  variability  [15],  and  that
exacerbated proinflammatory milieu in obese is associ-
ated with prediabetes and prehypertension [16].
Hypertension  [17]  and  dyslipidemia  [18].,  similarly
associated with increased CVD risk, are also intensified
by  the  overweight  and  obese  status.  Most  adults  with
HTN are overweight. The obese are six times more likely
to have high blood pressure compared to those that are
normal weight [17]. Asymptomatic overweight and obese
with  dysglycemia  (prediabetes),  dysregulation  of  blood
pressure  (prehypertension)  and/or  abnormal  metabolic
measures  (premetabolic  syndrome)  are  often  unrecog-
nized as having the metabolic syndrome [19]: a cluster of
risk factors with underlying systemic inflammation, insu-
lin resistance, and compensatory hyperinsulinemia [20].
Metabolic  syndrome  has  been  shown  to  be  related  to
myocardial  infarction  (OR,  2.01;  95%  CI,  1.53-  2.64),
stroke  (OR,  2.16;  95%  CI,  1.48-3.16),  and  myocardial
infarction/stroke (OR, 2.05; 95% CI, 1.64-2.57), in both
women and men [21].
Early  recognition  of  an  elevated  risk  for  developing
CVD  remains  highly  desirable  as  two  thirds  of  unex-
pected cardiac deaths occur in adults without prior rec-
ognition of disease [22]. A third of the women placed at
low risk with conventional risk assessment measures have
significant subclinical atherosclerosis [23]. At age 40, the
lifetime risk for coronary heart disease is 1 in 2 for men, 1
in 3 for women [24]; and for stroke, it is 1 in 6 for men, 1
in 5 for women [25]. With the alteration of conventional
risk assessors due to an increasing body weight, and the
largely unsubstantiated perceived increase in CVD risk in
clinically healthy adults with altered weight, newer meth-
ods for risk recognition are clearly warranted.
Normal blood pressure is characterized by a circadian
variation which includes generally higher day-time, and
lower night-time pressures, a night time descent and an
early morning surge. A spot blood pressure measured in a
physician's  office  is  an  isolated  cross-sectional  view  of
this circadian pattern and varies depending on the time of
the day it is obtained. Blood pressure automatically mea-
sured at fixed intervals for 7 days (with devices for ambu-
latory  use)  provides  ample  data  for  an  unequivocal
assessment of either normality or abnormality which is
undetected  by  spot  office  BP  measurements.  Resting
endothelial function obtained in a fasting state and dur-
ing fixed clock hours, is reflective of the early perturba-
tion caused by adverse cardiometabolic factors.
This study investigated the overall hypothesis that sub-
tle  changes  in  normal  circadian  BP  variability  and
endothelial  function  are  influenced  by  the  progressive
visceral  adipose  tissue  expansion,  the  accompanying
alteration of the metabolic milieu (glycemic and systemic
pro-inflammatory  changes)  and  the  overall  vascular
response  to  these  metabolic  perturbations.  Taken
together,  these  subtle  alterations  in  disease-free  obese
men  and  women  could,  over  the  long  term,  accelerate
cardiovascular disease related adverse events.
Materials and methods
Study design
Disease-free  (or  otherwise  healthy)  obese  men  and
women with no co-morbidities, screening for a weight
loss study at the Outpatient Clinic, Pennington Biomedi-
cal Research Center (PBRC), were offered an opportunity
to have 7-day automatic ambulatory blood pressure (BP)
monitoring  and  endothelial  function  assessment.  The
Pennington Biomedical Research Center is a campus of
the  Louisiana  State  University  System  and  conducts
basic,  clinical  and  population  research.  The  research
enterprise  at  the  Center  includes  80  faculty  and  more
than 40 post-doctoral fellows who comprise a network of
57 laboratories. These are supported by lab technicians,
nurses, dieticians, and support personnel, and 19 highly
specialized core service facilities. The Center's nearly 600
employees occupy several buildings on a 234-acre cam-
pus.
Each candidate was provided with the PBRC Institu-
tional Review Board approved informed consent and fol-
lowed  standard  consenting  procedures.  Fifteen  obese
adults agreed to participate in the automatic ambulatory
BP  monitoring  and  endothelial  function  assessment.
Demographic  and  anthropometric  information  along
with a resting EKG were obtained, followed by a compre-
hensive medical history and a complete physical exami-
nation.  The  initial  visit  ended  with  teaching  and
demonstration of the use, of an automatic blood pressure
monitor for ambulatory use. Upon completion of 7-day
ambulatory BP monitoring, a fasting blood draw, and a
resting endothelial function assessment were done. Com-
parison groups of 10 disease-free normal-weight, and 10
disease-free overweight adults were obtained from other
clinical trials. They also consented for automatic ambula-
tory BP monitoring and endothelial function assessment
and were processed in a similar fashion.
Study population
Healthy  (disease-free)  normal-weight,  overweight  and
obese (n = 35) non-smoking men and women betweenGupta et al. Cardiovascular Diabetology 2010, 9:58
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the ages of 30-75 years, with no personal history of or
ongoing treatment for any chronic medical conditions.
Inclusion/exclusion criteria
Apparently healthy men and women between the ages of
30-75 years, with no history of DM, HTN, DysL, MetS,
and/or CVD were included. Adults with a personal his-
tory of or ongoing treatment for diabetes, hypertension
or any other chronic cardiac, renal, gastro-intestinal, pul-
monary or any other systemic disease process requiring
chronic  intake  of  prescription  medications,  were
excluded.
Seven-day automatic ambulatory blood pressure 
monitoring
An automatic BP monitoring device (Spacelabs® Medical)
for ambulatory use was attached to a BP cuff to obtain BP
and heart rate (HR) readings at 30-min intervals during
the day (6:30 AM to 9:30 PM) and 60-min intervals at
night (10 PM to 6 AM) while the participants went about
their activities. Data were downloaded into the database
about  mid-way  and  at  the  end  of  the  7-day  recording
span.
Endothelial function by brachial ultrasound
Assessment of resting endothelial function was done in a
fasting state, after having avoided stimulants for 12 hours,
at the same fixed clock hour (range 8-10 AM), using a
Toshiba® brachial ultrasound device. This device uses 7.5
MHz multi-frequency linear array transducer and a MIA
Vascular Tools Brachial Analyzer Version 5.8.1 to deter-
mine brachial artery diameter. This technique has been
previously validated and is in use with our clinical core.
After obtaining reference (resting) brachial artery diame-
ter measures, a forearm BP cuff was used to occlude the
brachial artery for 5 minutes. The increase in brachial
artery diameter (over the reference measure) due to the
flow-mediated dilatation of the brachial artery after the
release of the occlusion, served as a measure of endothe-
lial  function.  One  subject  from  each  group  (normal-
weight, over-weight and obese without circadian blood
pressure  variability  abnormality)  had  a  measure  of
endothelial function. One obese subject with each of the
circadian variability abnormality (M-hypotension, CHAT
and EPP) also had endothelial function assessment.
Risks and discomforts
These non-invasive devices used a BP cuff that is inflated
and released to obtain BP readings and data on endothe-
lial  function.  The  automatic  ambulatory  BP  device
attached to a BP cuff under the clothes was placed on the
belt or carried in a pouch. Repeated measurements of BP
and HR at timed intervals over 7 days, while the partici-
pant was at work or at home, allowed for acclimatization
to the minimal discomfort, which is similar to having BP
measured.  Endothelial  function  was  also  obtained  by
using a BP cuff, coupled with an ultrasound probe that
measures  brachial  artery  diameter  at  rest  (reference),
during  occlusion  and  the  post-occlusion  increase  after
release.
Demographic, anthropometric and laboratory measures
Standard  demographic  and  anthropometric  measures
were obtained for all the participants. Waist circumfer-
ence (a surrogate marker for central adiposity), serum hs-
CRP  and  fibrinogen  (for  the  assessment  of  systemic
inflammation), fasting serum glucose and HbA1C (for the
assessment of glycemic status) and fasting complete lipid
profile (for the assessment of serum lipid sub-fractions,
and obtaining cardiac risk ratios) were obtained.
Normal-weight, overweight, obese, normoglycemia, 
prediabetes, prehypertension and premetabolic syndrome
Participants were placed into normal weight (BMI < 25
kg/m2)  overweight  (BMI  between  25-29.9  kg/m2)  and
obese (BMI > 30 kg/m2) categories. Normoglycemia and
prediabetes,  for  the  purpose  of  CVD  risk  assessment,
were defined as a fasting serum glucose less than 100 mg/
dL and a fasting serum glucose of more then 100 mg/dL
but less then 126 mg/dL, respectively (impaired fasting
glucose or IFG: ADA diagnostic criteria [26]). The diag-
nosis of prehypertension was based on resting (after a 5-
minute rest) mean of (two successive assessments 1 min-
ute apart) clinic BP measures of systolic (S) BP > 120 but
< 139 and/or diastolic (D) BP > 80 but < 89 mm Hg (JNC
7 criteria [27]). Premetabolic syndrome was defined using
the  diagnostic  criteria  for  the  metabolic  syndrome
(NCEP ATP III criteria), with the substitution of predia-
betes  and  prehypertension  criteria  for  glucose  and  BP
measures.
Data analysis and statistical methods
ABPM data gathered at the PBRC were electronically sent
to the Halberg Chronobiology Center, University of Min-
nesota for statistical analysis. Endothelial function data
were analyzed at the PBRC and then merged with the
ABPM data sent back from Dr. Halberg's laboratory. A
summary  in  time  (sphygmochron)  was  prepared  that
reported, among other measures, the midline-estimating-
statistic of rhythm (MESOR or M), the timing of high val-
ues  (acrophase),  and  the  extent  of  predictable  change
within a day (double circadian amplitude) for SBP, DBP
and HR. Normal circadian BP variability for SBP and DBP
over  a  24-hour  span  is  shown  in  Figure  1.  Seven-day
monitoring ensures the consistency of either normality or
abnormality over each one of the seven days and reports
the average over the seven-day span.Gupta et al. Cardiovascular Diabetology 2010, 9:58
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MESOR  Hypotension  (M-Hypotension)  or  MESOR
Hypertension (M-Hypertension) in this system is defined
as a BP MESOR below the lower 5% or above the upper
95% prediction limit of peers matched by age and gender.
M-Hypertension for SBP and DBP is shown in Figure 2.
Excessive  circadian  BP  excursion  (circadian  hyper
amplitude tension or CHAT) is a circadian double ampli-
tude for SBP and/or DBP above the upper 95% prediction
limit for peers. BP ecphasia is defined as an acrophase
(timing) for  BP (but not  HR)  occurring  outside  of  the
anticipated 90% prediction limits. HR variability is defi-
cient (DHRV) when the standard deviation (SD) of HR is
<  7.5  bpm.  Pulse  pressure  is  elevated  (EPP)  when  it
exceeds 60 mmHg. DHRV and EPP are shown in Figure 3
and Figure 4, respectively.
Day-night  ratios  were  also  computed  for  the  7-day
record as a whole and for each day separately, for a classi-
fication in terms of "dipping". Due to the normal daytime
BP being more  than  the  nighttime BP,  a negative  day-
night ratio was classified as "reverse dipping". A positive
day-night ratio between 10% and 20% was classified as
"dipping", whereas a ratio of less than 10% or greater than
20%  was  classified  as  "non-dipping"  or  "excessive  dip-
ping", respectively.
The occurrence of any of the above abnormal circadian
patterns of BP and/or HR, overall and for each day sepa-
rately, in terms of circadian characteristics and in terms
of the day-night ratio, was determined for each individual
in  the  three  groups  (normal-weight,  overweight  and
obese). Serial measurement over 7 days ensured the con-
sistency of either normality or abnormality. The groups
were compared using an Exact Test or Poisson regression
for frequency of occurrence data and Analysis of Variance
of quantitative measurements.
Results
Table 1 describes the clinical characteristics and details
the circadian BP variability abnormalities and endothelial
function  in  the  normal-weight,  overweight,  and  obese
adults. The 3 groups, consisting of normal-weight (Mean
± SD; 52 ± 13 y, range 32-71 y), overweight (52 ± 7 y,
range 40-62 y) and obese (56 ± 10 y, range 41-70 y) adults,
were not different in age, but by design had an incremen-
tal increase in weight and BMI. All of the twenty normal-
weight and overweight participants had normal circadian
BP variability, while 8 out of 15 obese participants had at
least one or more variety of abnormal circadian BP vari-
ability (four participants had one abnormality each, while
the other four had two variability abnormalities each) (p <
Figure 1 Normal circadian blood pressure variability.
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Figure 2 MESOR-hypertension.
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Figure 3 Acceptable and decreased heart rate variability.
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Figure 4 Acceptable and elevated pulse pressure.
Table 1: Clinical characteristics, circadian BP variability and endothelial function in disease free normal-weight, 
overweight and obese adults
Normal (n = 10) Overweight (n = 10) Obese (n = 15) P
Age (Y) 52 ± 12 52 ± 7 56 ± 10 NS *
Gender (W/M) 4/6 3/7 10/5 NS
Weight (kg) 64 ± 16 79 ± 14 95 ± 16 NA *
BMI (kg/m2) 22.6 ± 3 27.3 ± 3 33.9 ± 5 NA *
Waist Circ (cm) 79 ± 9 93 ± 10 117 ± 13 < 0.05 *
Abnormal CBPV 0/10 0/10 8/15 < 0.05 **
MESOR-Hypotension 0/10 0/10 5/15 < 0.05 **
MESOR-
Hypertension
0/10 0/10 2/15 NS
CHAT1 0/10 0/10 1/15 NS
EPP2 0/10 0/10 4/15 < 0.05 **
Total CBPV 
abnormalities
0/10 0/10 12/15 < 0.05 **
Endothelial 
Dysfunction
0/1 0/1 3/4 < 0.05 **
1Circadian Hyper-Amplitude Tension
2Elevated Pulse Pressure
DATA: MEAN ± SD
* Analysis of Variance
**Exact testGupta et al. Cardiovascular Diabetology 2010, 9:58
http://www.cardiab.com/content/9/1/58
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0.05; Exact Test). The 8 obese participants had a total of
twelve  circadian  BP  variability  abnormalities:  systolic
and/or  diastolic  MESOR-hypotension  (M-Hypotension:
5/10; p < 0.05) or -hypertension (M-Hypertension: 2/10),
excessive  BP  excursion  (CHAT:  1/10)  and/or  elevated
pulse pressure (EPP: 4/10; p < 0.05). Overall, of the total
fifteen obese participants, 7 obese participants had nor-
mal  circadian  variability  and  8  obese  participants  had
twelve circadian BP variability abnormalities. No abnor-
malities were found with the day-night ratios.
Normal-weight  and  overweight  participants  had  a
flow-mediated brachial  artery  dilatation  of  0.22  ±  0.06
and 0.20 ± 0.04 mm over resting (above reference) diame-
ter, respectively. Obese participants without circadian BP
abnormalities had a similar (to normal and overweight)
flow-mediated brachial  artery  dilatation  of  0.23  ±  0.02
mm over resting (above reference) diameter, compared to
an attenuated dilation of 0.18 ± 0.07, 0.12 ± 0.08, and 0.13
± 0.05 mm in those obese participants who had circadian
BP variability abnormalities (M-Hypotension, CHAT and
EPP, at 78, 52 and 56% of the expected; p = 0.3, 0.05 and
0.006, respectively).
Table 2 summarizes the cardiovascular disease risk pro-
file in the normal-weight (n = 10) and overweight (n = 10)
with normal CBPV and EF and the obese (n = 8) adult
participants  with  abnormal  CBPV.  The  normal-weight
and  overweight  participants  had  a  significantly  lower
mean  waist  circumference  than  the  obese  participants
with both the women and the men well below the entry
threshold of 88 and 102 cm, respectively, for inclusion in
the metabolic syndrome. The obese participants, on the
other hand with a statistically significantly higher waist
circumference met the criteria for inclusion into the met-
abolic  syndrome.  The  normal-weight  and  overweight
adults had a normal spot office SBP/DBP, pulse pressure
of 41 ± 7, 43 ± 8 mm Hg and heart rate of 67 ± 9, 74 ± 12
bpm. The 8 obese participants with abnormalities, how-
ever, had prehypertension (JNC 7 criteria: SBP 120-139
and/or DBP 80-80 mm Hg) with normal pulse pressure
and heart rate. The normal-weight and overweight par-
ticipants had normal fasting serum glucose, contrasted
with the 8 obese participants with abnormalities who had
prediabetes  (ADA  criteria:  FSG  100-125  mg/dL).  The
normal-weight and overweight participants had normal
lipid profiles with desirable total-C, triglycerides, HDL-C,
and LDL-C along with desirable cardiac risk ratios. The 8
obese participants with abnormalities had greater than
the desirable total-C, triglycerides, LDL-C and less than
desirable HDL-C. Their cardiac risk ratios were also over
the desirable range.
Table  3  compares  the  seven  obese  participants  with
normal circadian BP variability with the eight obese par-
ticipants who had abnormalities. The seven obese partic-
ipants  (BMI  32  kg/m2)  who  had  normal  circadian  BP
variability had normal glucose, hs-CRP, fibrinogen, trig-
lycerides, HDL-C and cardiac risk ratios. In contrast the
Table 2: CVD risk in disease free normal-weight and overweight subjects and in obese adults with CBPV abnormalities
Normal (n = 10) Overweight (n = 10) Obese (n = 8) P**
WC (Women < 88 
cm)*
71 ± 4 84 ± 6 109 ± 15 < 0.05
WC (Men < 102 cm)* 84 ± 7 97 ± 9 114 ± 6 < 0.05
SBP (< 120 mm Hg)* 113 ± 8 118 ± 10 129 ± 12 NS
DBP (< 80 mm Hg)* 72 ± 5 75 ± 5 80 ± 6 NS
FSG (< 100 mg/dL)* 89 ± 5 89 ± 8 102 ± 16 < 0.05
Total-C (< 200 mg/
dL)*
181 ± 23 180 ± 20 223 ± 38 < 0.05
LDL-C (< 130 mg/dL)* 109 ± 25 96 ± 13 133 ± 34 < 0.05
HDL-C (> 50 mg/dL)* 63 ± 4 54 ± 16 46 ± 13 NS
TG (< 150 mg/dL)* 49 ± 12 112 ± 60 220 ± 111 < 0.05
Total-C/HDL-C ratio 
(< 5)*
2.9 ± 0.6 3.6 ± 0.9 5.2 ± 1.9 NS
LDL-C/HDL-C ratio (< 
3)*
1.7 ± 0.5 1.9 ± 0.7 3.1 ± 1.4 < 0.05
Numbers in Italics are outside the desirable range
DATA: MEAN ± SD
* (In parenthesis: Desirable values)
** Analysis of VarianceGupta et al. Cardiovascular Diabetology 2010, 9:58
http://www.cardiab.com/content/9/1/58
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eight obese subjects with abnormal circadian BP variabil-
ity exhibited majority of the CVD risk parameters outside
of the desirable range.
Figure  5  details  the  pro-inflammatory  milieu  in  the
obese adults. Panel (5 A) depicts serum high sensitivity
C-reactive protein (hs-CRP) concentrations in the obese
adults with normal and abnormal circadian BP variability.
Obese adults with no abnormalities (n = 7) had normal
hs-CRP concentrations of (Mean ± SEM) 1.9 ± 1.7 mg/L.
Participants with abnormal circadian BP variability disor-
ders: M-Hypotension (n = 5) had hs-CRP concentration
of 19.2 ± 3.1 mg/L (p < 0.05), with M-Hypertension (n =
2) 3.1 ± 0.1 mg/L (p < 0.05), with CHAT (n = 1) 20.2 mg/L
and with EPP (n = 4) 10.9 ± 6 mg/L. Panel (5 B) depicts
serum fibrinogen concentrations in the obese adults with
normal  and  abnormal  circadian  BP  variability.  Obese
adults with no abnormalities (n = 7) had normal fibrino-
gen concentrations (Mean ± SEM) of 411 ± 18 mg/dL.
Participants with abnormal circadian BP variability disor-
ders: M-Hypotension (n = 5) had fibrinogen concentra-
tion of 638 ± 38 mg/dL (p < 0.05), with M-Hypertension
(n = 2) 477 ± 7 mg/dL, with CHAT (n = 1) 600 mg/dL and
with EPP (n = 4) 581 ± 60 mg/dL.
Figure 6 details the glycemic milieu in the obese adults.
Panel (6 A) depicts fasting serum glucose (FSG) concen-
trations in the obese adults with normal and abnormal
Table 3: CVD risk in disease free obese adults without and 
with abnormal CBPV
Obese with 
Normal CBPV (n 
= 7)
Obese with 
Abnormal CBPV 
(n = 8)
BMI (kg/m2) 32 ± 5 36 ± 3
WC (F < 88 cm)* 95 ± 13 113 ± 13
WC (M < 102 
cm)*
109 ± 13 111 ± 5
SBP (< 120 mm 
Hg)*
121 ± 12 129 ± 12
DBP (< 80 mm 
Hg)*
82 ± 5 80 ± 6
FSG (< 100 mg/
dL)*
94 ± 6 102 ± 16
hs-CRP(< 3.0 
mg/L)*
1.9 ± 1.7 15 ± 9
Fibrinogen (< 
450)*
411 ± 13 593 ± 97
HDL-C (> 50 mg/
dL)*
52 ± 12 46 ± 13
TG (< 150 mg/
dL)*
117 ± 47 133 ± 35
Total-C/HDL-C 
ratio (< 5)*
3.9 ± 0.7 5.2 ± 1.9
LDL/HDL-C ratio 
(< 3)*
2.4 ± 0.6 3.1 ± 1.4
Numbers in Italics are outside the desirable range
DATA: MEAN ± SD
* (In parenthesis: Desirable values)
Figure 5 Pro-inflammatory milieu in obese adults. (A): hs-CRP: nor-
mal and abnormal CBPV. (B): fibrinogen: normal and abnormal CBPV.
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Figure 6 Glycemic milieu in obese adults. (A): FSG: normal and ab-
normal CBPV. (B): HbA1c: normal and abnormal CBPV.
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circadian BP variability. Obese adults with no abnormali-
ties  (n  =  7)  had  normal  FSG  concentrations  (Mean  ±
SEM) of 94 ± 6 mg/dL. Participants with abnormal circa-
dian BP variability disorders: M-Hypotension (n = 5) had
FSG of 102 ± 2 mg/dL (p < 0.05), with M-Hypertension (n
= 2) 111 ± 24 mg/dL, with CHAT (n = 1) 85 mg/dL and
with EPP (n = 4) 105 ± 11 mg/L. Panel (6 B) depicts per-
cent  glycosylated  hemoglobin  (HbA1C)  in  the  obese
adults with normal and abnormal circadian BP variability.
Obese adults with no abnormalities (n = 7) had normal
HbA1C (Mean ± SEM) of 5.5 ± 0.05%. Participants with
abnormal circadian BP variability: M-Hypotension (n = 5)
had HbA1C of 5.8 ± 0.3% (p < 0.05), with M-Hyperten-
sion (n = 2) 5.9 ± 0.6%, with CHAT (n = 1) 5.4% and with
EPP (n = 4) 6.1 ± 0.3%.
Figure  7  illustrates  the  normal  and  abnormal  flow-
mediated brachial artery dilation curves in a representa-
tive obese adult with and without circadian BP variability
abnormalities.  Brachial  artery  dilation  upon  release  of
occlusion above the resting (reference) measure reported
in  millimeters  is  the  measure  of  endothelial  function.
Panel (7 A) shows an increase in brachial artery diameter
after  release  of  brachial  artery  occlusion,  representing
normal endothelial function in an obese adult with no
circadian BP variability abnormalities. Panel (7 B) shows
a flatter brachial artery diameter after release of brachial
artery occlusion, representing endothelial dysfunction in
an obese adult with circadian BP variability abnormali-
ties.
Discussion
The data from this study show that only those asymptom-
atic (disease free) obese adults (that had prediabetes, pre-
hypertension,  elevated  systemic  inflammation  and
cardiac  risk  ratios),  when  compared  with  disease-free
normal-weight, overweight and obese adults (with nor-
moglycemia, desirable blood pressure, systemic inflam-
mation and cardiac ratios) have significant circadian BP
variability  abnormalities  and  endothelial  dysfunction.
Circadian  variability  of  blood  pressure  and  heart  rate
measured  over  7  days  provides  a  dynamic,  functional
assessment of the cardiovascular system. It also ensures
the consistency of either normality, or abnormality of the
circadian BP variability measures. Both the obese partici-
pants with M-Hypertension also had an elevated pulse
pressure. Of the five obese participants with M-Hypoten-
sion, two also had an elevated pulse pressure. Thus four
of  the  eight  participants  with  abnormal  BP  variability
had, not one, but two varieties of circadian BP variability
abnormalities  (8  obese  participants  had  12  variability
abnormalities).  Normal-weight,  overweight  and  obese
participants had a flow-mediated brachial artery dilata-
tion  of  0.22  ±  0.06,  0.20  ±  0.04  and  mm  over  resting
(above reference) diameter, compared to an attenuated
dilation of 0.18 ± 0.07, 0.12 ± 0.08, and 0.13 ± 0.05 mm in
those obese participants who had circadian BP variability
abnormalities.
Abnormal circadian BP variability, endothelial function and 
cardiovascular morbidity and mortality
The  effect  of  abnormal  circadian  BP  variability  upon
untoward  cardiovascular  events  is  both  separate  and
additive.  Having  more  than  one  abnormality  increases
this risk: In a reference population of 214 patients (some
with  M-Hypertension)  presenting  with  none  of  the  3
abnormal variability measures (decreased heart rate vari-
ability (DHRV), EPP, or CHAT), morbidity within a 6-
year follow-up was found in 8 cases (3.7%). The presence
of one abnormality (DRHV or EPP) alone raised the inci-
dence of morbidity to 30.8%. When these two risk factors
(DRHV and EPP) were both present, morbidity was dou-
bled (66.7%). The presence of CHAT increased morbidity
from 3.7% to 23.5% in the absence of the other two risk
Figure 7 Endothelial function in obese adults. (A): Normal CBPV. 
(A): Abnormal CBPV.
￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
￿￿￿
￿￿￿
￿￿￿
￿￿￿
￿￿￿￿￿￿￿￿￿￿￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
￿￿￿
￿￿￿
￿￿￿
￿￿￿
￿￿￿
￿￿￿￿￿￿￿￿￿￿￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
A)
B)Gupta et al. Cardiovascular Diabetology 2010, 9:58
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factors, from 30.8% to 50% when either DHRV or EPP
was also present, or from 66.7% to 100% when all 3 risk
factors are present [28]. Halberg et al. [29] have shown
that even in the absence of conventional CVD risk factors
(like DM, HTN, and DysL); abnormalities in circadian BP
variability are risk factors for CVD and early death. Oth-
ers have shown the superior predictive ability of ambula-
tory  BP  monitoring  data  vs.  conventional  office  BP
measures in adults with hypertension.
The endothelium is a highly active organ which regu-
lates intravascular homeostasis by integrating numerous
functions such as glycemia, blood pressure, pro-inflam-
matory/anti-inflammatory  processes  and  coagulation.
Endothelial  dysfunction,  the  initial  perturbation  in  the
process  of  atherosclerosis,  in  asymptomatic individuals
portends  increased  vascular  disease  risk  [30].  Obese
adults  with  abnormal  circadian  BP  variability  (M-
Hypotension, CHAT, and EPP) also had endothelial dys-
function  (flow  mediated  brachial  diameter  increase  of
0.18(0.07),  0.12(0.08),  and  0.13(0.05)  mm  over  resting
diameter or flow mediated dilation at only 78, 52, and
56% of the resting diameter, respectively, p <0.05). Abnor-
malities of both these measures: abnormal circadian BP
variability (reflective of the functional aspects of the car-
diovascular system), and endothelial dysfunction (reflec-
tive of a sum total of various effectors including glycemia,
blood pressure, coagulation, pro-inflammatory and anti-
inflammatory  factors)  in  asymptomatic  (disease  free)
obese adults are novel non-invasive methods for assess-
ing the dynamic aspects of cardiovascular disease risk.
Recognized CVD risk factors
Gradual weight gain in clinically healthy overweight and
obese  adults  is  preferentially  manifest  as  an  enlarging
waist  circumference  [31].  Abdominal  obesity,  clinically
measured as an increased waist circumference and sug-
gestive of an expanding visceral adipose tissue compart-
ment,  has  an  independent  association  with  coronary
heart disease [32]. Visceral adipose tissue, which strongly
correlates  with  most  metabolic  risk  factors  [33],  upon
expansion,  alters  its  usual  and  customary  adipokine
secretion menu [34]. There is an increased flux in the fac-
tors influencing the pro-inflammatory and renin-angio-
tensin-aldosterone system, in parallel with attenuation in
the  anti-inflammatory  factors.  The  altered  pro-inflam-
matory  (increased)  and  anti-inflammatory  (decreased)
balance,  among  other  reasons  promotes  insulin  resis-
tance [35]. Elevated HbA1c is related to new onset CVD
over a relatively short follow-up period in both men and
women without diabetes, who do not develop diabetes,
even after adjustment for other major risk factors [36].
Dysregulated pro-inflammatory: anti-inflammatory bal-
ance, increased serum hs-CRP [37], total leukocyte count
[38], serum uric acid [39], and decreased adiponectin [34]
are associated with increased cardiovascular disease. Dis-
ease-free  obese  with  an  exacerbated  proinflammatory
milieu exhibit prediabetes and prehypertension [16]. Pre-
diabetes is associated with abnormal circadian BP vari-
ability [15], prehypertension clusters with other CVD risk
factors [40] and metabolic syndrome more strongly pre-
dicts  CVD  than  its  individual  components  [41].  An
imbalance between the central and the peripheral clock
mechanisms has recently been suggested as the cause for
the endothelial function [42]. 24-hour ambulatory blood
pressure measures have been used to predict target-organ
disease and clinical outcome in patients with hyperten-
sion [43] and more recently, elevations in nocturnal BP
have  been  shown  to  precede  diabetic  nephropathy  in
hypertensive patients with T2DM [44].
Overweight  or  obese  adults  with  larger  than  normal
waistline, along with subtle metabolic alterations, either
with elevated FSG (prediabetes [26], elevated SBP and/or
DBP (prehypertension [27]), and/or a combination of risk
factors  (premetabolic  syndrome)  are  commonplace  in
routine clinical practice. These adults with unrecognized
elevated CVD risk, more often than not, are lost to regu-
lar follow-up. This results in a lost opportunity for pri-
mary prevention of CVD. We believe that increased CVD
in  asymptomatic  normal-weight,  overweight  and/or
obese adults can readily recognized by the abnormal cir-
cadian BP variability, and endothelial dysfunction. Non-
pharmacologic, as well as pharmacologic measures can
be  utilized  to  reverse  these  early  abnormalities.  Non-
pharmacologic measures: a 7% weight loss from reference
(improving glycemia), and increasing physical activity up
to 150 minutes per week, (improving both glycemia and
blood pressure) could be advocated. Pharmacologic mea-
sures: treatment with thiazolidinediones (reducing insu-
lin resistance and pro-inflammatory milieu, along with
remodeling of the adipose tissue), biguanides (reducing
insulin resistance), angiotensin converting enzyme inhib-
itors  or  angiotensin  receptor  blockers  (reducing  blood
pressure,  improving  glycemia  and  systemic  inflamma-
tion) and HMG-CoA reductase inhibitors or statins (sys-
temic  inflammation,  improving  cardiac  risk  ratios  and
endothelial function) could be utilized.
The results from this study show that latent CVD risk
in disease-free (healthy) obese adults assessed with no or
low risk by conventional risk assessment methods, can be
unmasked by simple non-invasive measures. The obese
participants  exhibiting  normal  circadian  BP  variability
had normal endothelial function, normotension, normo-
glycemia and were within the desirable limits for systemic
inflammation,  triglycerides,  HDL-C,  and  cardiac  risk
ratios. Asymptomatic obese participants with abnormal
circadian BP variability and endothelial dysfunction also
had:  an  increased  visceral  adipose  tissue, a heightened
pro-inflammatory  profile,  prediabetes,  prehypertensionGupta et al. Cardiovascular Diabetology 2010, 9:58
http://www.cardiab.com/content/9/1/58
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and abnormal cardiac risk ratios. Abnormal circadian BP
variability  and  endothelial  dysfunction,  taken  together
with  the  altered  adverse  cardiometabolic  profile,  are
indicative of an unrecognized CVD risk in disease free
obese men and women.
Study limitations
The study has several limitations that warrant discussion.
The study participants were adult asymptomatic volun-
teers who were screening for various clinical studies at
the Pennington Center, and may not be representative of
the  general  population.  Further,  it  is  a  cross-sectional
study in which the temporal sequence of emergence of
dysregulated assessments is unknown. Finally, the small
sample size may have compromised the power to detect
population differences among the normal-weight, over-
weight, and obese groups. Despite these shortcomings,
this investigation documents statistically significant novel
findings  of  a  clinical  correlation  between  circadian  BP
variability  and  endothelial  function  abnormalities  and
systemic  proinflammation,  prediabetes,  prehyperten-
sion, elevated cardiac risk ratios, and establishes a foun-
dation  for  further  investigation  of  the  underlying
mechanisms.
Conclusion
While  studies  with  larger  numbers  of  participants  are
clearly indicated, these findings taken in conjunction with
the recognized subtle abnormal circadian BP variability
in prediabetes [15] strengthen our overall hypothesis that
progressive  visceral  adipose  tissue  expansion  with  the
accompanying systemic pro-inflammatory and glycemic
changes [16] and the overall vascular response to these
metabolic perturbations, influence circadian BP variabil-
ity and endothelial function. Taken together with other
anthropometric and laboratory measures, these are indic-
ative of an enhanced CVD risk. Circadian BP variability
and endothelial function, along with subtle abnormalities
of pro-inflammatory and glycemic milieu, can be novel
measures for recognizing latent CVD risk in otherwise
asymptomatic obese and possibly in other populations.
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